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Genomic organization of a human cystine transporter gene (SLC3AI)
and identification of novel mutations causing cystinuria. Cystinuria is a
common inherited aminoaciduria that leads to recurrent cystine nephro-
lithiasis. Mutations in a gene encoding a renal amino acid transporter
(SLC3AI) have been identified in patients with cystinuria establishing one
molecular cause for the disease. To facilitate systematic screening of this
gene for mutations, we have delineated the complete genomic organiza-
tion of the SLC3AJ coding region using polymerase chain reaction
strategies. The complete coding region of the gene is contained within a
single yeast artificial chromosome clone and consists of 10 exons and 9
introns. Oligonucleotide primers capable of amplifying selected exons
have been made and used in mutational analysis of DNA from 24
cystinuria probands. We illustrate the usefulness of this approach by
identifying two novel SLC3AJ mutations. One novel mutation causes
replacement of a highly conserved arginine residue (arginine-452) with
tryptophan in the cytoplasmic loop between the putative third and fourth
membrane spanning segments. A second previously unreported mutation
results in replacement of a highly conserved tyrosine (tyrosine-461)
residue with histidine in the same region of the protein. In addition, we
detected three previously reported SLC3AI mutations, R270X, 1500
+1/G toT, and M467T, the latter being present in —20% of cystinuria
chromosomes examined. Our findings provide a foundation for the
development of more accessible diagnostic screening assays for detecting
SLC3AI mutations using patient genomic DNA, and also contribute to the
emerging spectrum of cystinuria genotypes.
Cystinuria is an autosomal recessive disorder that leads to
recurrent nephrolithiasis. The disease is caused by an inherited
defect in the transport of cystine and dibasic amino acids (argi-
nine, lysine, ornithine) across the apical membranes of proximal
renal tubular and jejunal epithelial cells and has an incidence of
between 1:7000 and 1:12000 [1]. Cystine is poorly soluble in urine
and its precipitation results in the formation of stones. Recurrent
cystine nephrolithiasis occurs throughout the patient's lifetime
and is often associated with significant morbidity.
A candidate gene for cystinuria was identified recently by three
groups using expression cloning strategies in Xenopus oocytes
[2—41. The —680 amino acid protein (designated as D2, or rBAT)
encoded by this gene exhibits Na independent transport of
cystine and dibasic amino acids when expressed in oocytes [2—41,
and is localized to the microvilli of the S3 segment of proximal
tubule [5]. Human cystine transporter eDNA sequences were
reported subsequently [6, 7], and the corresponding gene (desig-
nated as SLG3AJ) has been assigned to human chromosome 2
(2p2l) [8, 91• This chromosomal localization correlated well with
that determined by linkage analysis in cystinuria pedigrees [10].
Direct demonstration of SLC3AI mutations was first reported
in 1994 by Calonge et al [11], thus confirming its role as a
cystinuria gene. Several additional mutations have been found in
SLC3AJ which co-segregate with the cystinuria phenotype [12—
14]. Functional characterizations of certain missense mutations
have revealed reduced transporter activity consistent with the
physiologic defect that exists in the disease [ii, 12]. In many cases,
the detection of SLC3AJ mutations has relied upon illegitimate
transcription of mRNA from this gene in lymphoblastoid cell lines
established from peripheral blood leukocytes of cystinuric pa-
tients [11—14]. This is a time consuming and labor intensive
process which requires an initial delay of several weeks for
establishment of the lymphoblastoid lines. Furthermore, this
approach is not optimal for delineating mutations affecting critical
splice junction sequences. Additional mutations have been found
using information regarding the partial genomic organization of
the gene [13—15].
To facilitate the ascertainment of SLC3AJ mutant genotypes,
we have defined the complete genomic organization of the
SLC3A1 coding region, and developed exon-specific oligonucleo-
tide primers for use in mutational analysis. We further demon-
strate the utility of this approach by identifying five mutant alleles
including two novel missense mutations. This information will
facilitate the identification of other SLC3A I mutations, contribute
to our understanding of the molecular basis of cystinuria, and
provide the foundation for genotype-phenotype correlations.
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Genomic cloning of SLC3AJ
The cDNA sequence coding for human D2 [7] (Gen Bank acces-
sion number M95548) was used to design oligonucleotide primer
1893
1894 Endsley et al: Cystinuria and SLC3AJ gene mutation
Table 1. Exon-specific polymerase chain reaction oligonucleotide primers for SLC3A1
Exon Forward
IA 5'-TTATGTCTFCGGAGTGCCTTC
1 B 5'-TACCGCATACCTCGGGAGAT
2 5'-AACAAAGTAGGGmATTCAT
3 5'-GACAGGAAAATATACTGATFA117
4 5'-ATGTGCTGVFFTCTFTGm
5 5'-GCCAACCAIT1TGCTI7CTTC
6 5'-AATGTATGAAATGAGGGTAACC
7 5 '-AATCGCTGTCCTCTCCTTCTGTG
8 5'-TCTGTGAAATAGGGTAAATCT
9 5'-CTGlTVFCCC'TTTCTGGTCTT
1OA 5 '-CCTACTFATFGATGCTFACA
lOB 5 -AATCTITATCGTGGTTCTGA
Reverse
5 '-CACCAGCACAGAAGCCACTG
5'-CTGAAGAACAAAAGAACCATA
5'-GAGGGAGGGAGGGAAAGAAA
5'-GGAGAGAAAATAGGmGAAT
5 '-GAAGTCTGTGTGGGTATCTA
5 -ACACTCTGATGACA'VITTCA
5 '-GCCTGGGAAGAAATGAGAGC
5 '-TCCTCTCCTTACTCTGCTGTCAT
5'-CCTATCAGGTAGAAAACATCT
5'-GAATAGACAATACTAATCCGTFA
5'-CAGTGTTGATTCTCCAAAAT
5 '-GCCAGTGTCTTCATCTCTTC
Size Temperature
329 bp 52
256 hp 51
345 bp 54
457 bp 50
178 bp 52
206 bp 52
204 bp 54
312bp 53
496 bp 52
262 bp 52
344 bp 50
316 bp 49
pairs to amplify SLC3AJ segments from genomic DNA using the
polymerase chain reaction (PCR). Reactions using primer pairs
Bf181 7/Br1964 (C-terminus; Bfl 817: 5 '-AATClTFATCGTGGT-
TCTGA-3'; BrI 964: 5 '-TGAGTCCCTCTCCCTTGTCC-3') and
Bf13/Br322 (N-terminus; Bf13: 5'-'TTATGTCYT'CGGAGTGC-
CTTC-3'; Br322: 5'-CACCAGCACAGAAGCCACTG-3') were
both successful in amplifying 166 bp (nucleotides 13 to 341) and
329 bp (nucleotides 1817-1982) products, respectively, from hu-
man genomic DNA that were co-linear with the human D2 eDNA
as determined by direct sequencing. The Bf1817/Br1964 primer
set was then used to screen the CEPH megaYAC human genomic
library (provided in microtiter well format by Research Genetics,
Huntsville, AL, USA). Reactions were performed using 35 cycles
of 94°C one minute, 48°C one minute, and 72°C one minute, and
a final MgC12 concentration of 2 m. Three positive clones were
identified. Yeast DNA was isolated from 10 ml liquid cultures by
the method of Hoffman and Winston [16] and re-screened for the
presence of SLC3AI sequences using the Bf1817/Brl 964 primer
set. Two clones were shown to be false positives. Clone
yhCEPH888G9 was positive and was used for delineation of
genomic organization.
Definition of SLC3AJ intron-exon boundaries
To screen for intron-exon boundaries, we initially employed vec-
torette PCR [17]. Yeast DNA isolated from clone yhCEPH888G9
was digested with one of three restriction enzymes AluI, RsaI, or
Hinfl), and the resulting restriction fragments were then ligated to
specialized double stranded DNA linkers (vectorettes) as de-
scribed [17]. The resulting vectorette libraries were then used as
templates in PCR reactions consisting of an SLC3AJ coding
sequence primer paired with a vectorette specific primer. Single
band products obtained in these PCR reactions were directly
sequenced after spin column purification (Qiagen, Corp). In the
case of multiple products, Southern blot hybridization with a
nested [32P] end-labeled oligonucleotide probe was performed.
Positively hybridizing products were gel purified, suhcloned into
the pCRII plasmid vector, verified by colony hybridization, and
then sequenced.
To define intron-exon boundaries not fully discerned with
vectorette PCR, we utilized either intron-bridging PCR or inverse
PCR [18]. For the latter, YAC DNA was digested with one of
three restriction enzymes (Sau3AI, HhaI, or TaqI) and the
resulting fragments were self-ligated under conditions that fa-
vored circularization. PCR primers designed to extend outward in
both directions from a known sequence were employed to create
products bridging the ligated ends. Products of inverse PCR re-
actions were processed identically to those of vectorette reactions.
Splice sites were located by identifying consensus splice junc-
tion sequences at points of divergence between the eDNA and
PCR-generated genomic sequence using computer alignments.
For each exon, an overlapping sequence in both directions was
obtained. Splice junctions were sequenced in both directions.
Single-strand conformational analysis (SSCA)
Twenty-four blood samples were obtained from patients with
well-documented cystinuria as defined by a history of recurrent
renal stones and elevated urine cystine level. In most cases, we
were unable to assign the allelie type of cystinuria because of the
lack of urinary cystine excretion data on related heterozygous
carriers. Genomic DNA was isolated by a standard phenol-based
method [19], Exon-specific oligonucleotide primers were designed
based upon genomic sequence data, and tested by PCR amplifi-
cation of human DNA to confirm the expected product size
(Table 1).
For SSCA, genomic DNA samples were amplified by PCR (8
mm at 94°C, followed by 30 cycles of 94°C for 1 mm, annealing
temperature for 1.5 mm, and 72°C for 1.5 mm) using exon-specific
primer pairs. Reaction mixtures (final volume 10 1.d) contained
the following: 200 ng DNA, 0.5 .tM each PCR primer, 70 LM each
deoxynucleoside triphosphate, 10 mt Tris (pH 8.3), 50 mvi KC1,
0.01% gelatin, 1.5—2.0 mt MgCI2, 0.25 units of Taq DNA
polymerase (Boehringer Mannheim), and 0.1 d of [a-32P]-dETP
(3000 Ci/mmol). Following amplification, PCR products were
diluted with 50 jd of 0.1% SDS/l0 mt EDTA. AS 1.d sample of
each diluted reaction was then mixed with 6 rl of gel loading dye
(95% formamide, 20 mivi EDTA, 0.05% bromophenol blue, 0.05%
xylcne cyanol EF). Samples were heat denatured at 94°C for five
minutes, chilled on ice, and 3pi loaded onto 0.5X MDE gels (J.T.
Baker, Inc.). Gels were electrophorcsed 14 hours at 8 watts
constant power in Tris-borate-EDTA buffer. After electrophore-
sis, gels were transferred to blotting paper, dried, and subjected to
autoradiography.
Nucleotide sequence determination
Direct sequencing of PCR products was performed using the
original amplification primers and the DyeDeoxy terminator cycle
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A
MAEDKSKRDSIEMSMKGCQTNNGFVHNEDILEQTPDPGSSTDNLKHSTRGILGSQEPDFKGVQPYAGMPK 70
EVLFQFSGQARYRIPREILFWLTVASVLVLIAATIAIIALSPKCLDWWQEGPMYQIYPRSFKDSNKDGNG 140
DLKGIQDKLDYITALNIKTVWITSFYKSSLKDFRYGVEDFREVDPIFGTMEDFENLVAAIHDKGLKLI ID 210
A A
FIPNHTSDKHIWFQLSRTRTGKYTDYYIWHDCTHENGKTIPPNNWLSVYGNSSWHFDEVRNQCYFHQFMK 280
A
EQPDLNFRNPDVQEEIKEILRFWLTKGVDGFSLDAVKFLLEAKHLRDEIQVNKTQIPDTVTQYSELYHDF 350
A A
TTTQVGMHDIVRSFRQTMDQYSTEPGRYRFMGTEAYAESIDRTVMYYGLPFIQEADFPFNNYLSMLDTVS 420
A
GNSVYEVITSWMENMPEGKWPNWMIGGPDSSRLTSRLGNQYVNVMNMLLFTLPGTP ITYYGEEIGMGNIV 490
AANLNESYDINTLRSKSPMQWDNSSNAGFSEASNTWLPTNSDYHTVNVDVQKTQPRSALJKLYQDLSLIJHA 560
A A
NELLLNRGWFCHLRNDSHYVVYTRELDGIDRIFIVVLNFGESTLLNLHNMISGLPAKIRIRLSTNSADKG 630
SKVDTSGIFLDKGEGLIFEHNTKNLLHRQTAFRDRCFVSNRACYSSVLNILYTSC 685
B +1
TATA Box
Rat TTTACCCTTTCTTCCTTGGCTGGACTTTGTCCAGCCAGGATTATTTATAAACCATTCAAAGCTCATTAATAAACCACAGCACCCAGCAAGCCAC
I liii
Human
Rat CTTTTCAC -TCTCTCCCTACTGGApAGCACTGGGMGAGCTGCACCGGATAGACApG
LW I HI
Human TCTTCCACCTCCCTTACTGCAGCAGGCACTCCGAAGACATAAGTCGGTGAGACAPG
Exon 1 Met-P
Fig. 1. Location SLC'3A1 introns. A. Amino acid sequence (single letter abbreviation) deduced from the human D2 cDNA [71 shown with intron
positions marked by""" beneath the protein sequence. The locations of the putative membrane spanning segments are shown by horizontal lines below
the sequence. B. Nucleotide sequence alignmcnt of human and rat SLC3AJ exon and adjacent 5' flanking sequence. Transcription start site in the rat
sequence is indicated by +1, and a TATA box motif and translation start site (ATG) are indicated by boldface type.
sequencing method (Applied Biosystems, Inc.). Sequencing reac- DNA allowed to elute overnight at room temperature. Ten
tions were electrophoresed and detected on an Applied Biosys- microliters of eluted DNA were re-amplified using the original
tems model 377 automated sequencer. For sequencing of abnor- primers, and the resulting products were purified by spin column
mal SSCA conformers, individual bands were carefully excised chromatography (Qiagen) before cycle sequencing. Sequence
from dried gels, placed into 100
.d of deionized water, and the variants were confirmed by sequencing the complementary strand.
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...GAT CTG AAA G gtacatgcccD L K
...CAT OAT AAA gtggggcaagH D K
...AAC AACTOGgtaagatcaN N W
...GAA ATA AAA gtggagtata
E I K
...CAA ATC CCG gtaaagtttt
Q I P
...AGA TAC AG gttgaccacgRY R
...AAC TGG ATG gtaagttctcNW M
TAT GAT AlT gtaagttgaaY DI
...AAT GlT OAT gtaagtatcaN V D
12 34 5 6 1234 5 6 7 8 9 10 11 12 13
Exon 4 Exon 8
Fig. 2. Autoradiographs of representative SLC3AJ exon 4 and exon 8 single-strand conformationalpolymo,phisms in several cystinuria prohands. Arrows to
the right or left of the panels indicate the electrophoretically abnormal bands.
Allele-specific oligonucleotide hybridization
An oligonucleotide probe (5 '-ACAGTTCATGGCTGACT-3')
was synthesized to match the sequence of the R452W allele.
Genomic DNAs (200 ng) from affected individuals with the
R452W allele and 97 normal controls were amplified using the
exon 8 primer pair, and 10 p1 of each product were alkali
denatured (0.4 M NaOH/25 mivi EDTA), then applied to nylon
membranes (Hybond-N, Amersham Corp.) using a slot-blot ap-
paratus (Schleicher and Schuell). Membranes were heat and UV
fixed then prehybridized for one hour in 5 X SSPE, 5x Den-
hardt's solution, and 1% SDS. The allele-specific probe was
end-labeled using T4 polynucleotide kinase in the presence of
[32P]-y-ATP. Unincorporated nucleotides were removed by G-25
Sephadex spin column chromatography. Hybridizations were
done at 48°C for four hours with 0.3 to 0.6 x 106 cpm/ml of the
end-labeled probe. Filters were washed three times with I x
SSPE/0.1% SDS for 20 minutes at the hybridization temperature,
and subjected to autoradiography.
Results
Genomic cloning of SLC3AJ
Without prior knowledge regarding the size of the SLC3AJ
gene, we elected to use a reference human genomic library
constructed in yeast artificial chromosomes (CEPH Mega-YAC
library) capable of carrying up to I megabase inserts. We used a
PCR-based screening strategy employing a primer pair designed
to amplify a 166 bp product corresponding to part of the
carboxyl-terminus of SLC3AJ from human genomic DNA. This
strategy permitted isolation of a single YAC clone (yhCEPH888G9,
940 kb) that contains the gene. This clone contained the complete
SLC3AI coding region as demonstrated by successfully amplifying
sequences from the extreme regions of both the amino- and
carboxyl termini.
Definition of intron-exon boundaries
To define splice junctions in SLC3AJ, we initially employed
vectorette PCR using an ordered set of oligonucleotide primers
Table 2. Catalog of SLC3AI splice junctions
Acceptor site° Exon bp Codon Donor site
1(461) 1-143"
ttttcttcag GT AYF CAA... 2 (178) 144-203GIW
aacccattag GGT TFA AAA... 3 (152) 204-2550 L K
tgtttgccag TTA AGT GTG... 4 (125) 256-297L S V
tcatctttag GAA ATF hA... 5 (119) 298-337
E I L
gttttcaaag GAC ACG GTC... 6 (134) 338-379D TV
actcttatag G TTCATG GGC... 7(195) 380-444F M 0
tgcctttcag ATI GGT GGA... 8 (167) 445-500
I C G
tttgacatag AAT ACC CiT.. 9 (116) 501-539NT L
aaaaaaatag GTC CAA AAG... 10(440) 540-686'V OK
__ __ __ ___ __ ___
Intron sequences have been deposited in GenBank (Accession numbers U60810-U60819).
Intron sequence in lower case letters, exon sequence with translation beneath in upper case letters
"Includes partial sequence of the 5-untranslated region
Includes partial sequence of the 3-untranslated region
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CAG ACAGTTCATGGCTG ACTTCGCG
.1
TGGG GAATCAGCATGTC TACGTG
Fig. 3. Nucleotide sequence chromatographs of two novel SLC3AJ muta-
tions. Partial nucleotide sequences of R452W (top) and Y461H (bottom)
mutant alleles are shown. Vertical arrows indicate the changed nucleotide,
and the affected codon is underlined.
designed to anneal at 150 to 200 bp intervals along the coding
sequence of the gene on both strands. Vectorette PCR was
originally developed to aid in the isolation of end-sequences in
YAC DNA [17], but has been used successfully to delineate
intron-exon boundaries in complex human genes [20, 21]. Approx-
imately two thirds of the SLC3A1 coding sequence was isolated
using this approach, and nearly all of the splice junctions were
identified on at least one intron-exon boundary. To obtain the
remaining splice junction sequences, we used either direct intron-
spanning PCR or inverse PCR. Use of all three techniques yielded
information about the complete intron-exon organization of the
SLC3AJ coding region without the need for high resolution
restriction mapping or the subcloning of the YAC clone.
The gene consists of ten exons, ranging in size from 116 to 474
base pairs. The first and last exons are the largest, approximately
four times larger than the intervening exons, which are all
between 100 and 200 base pairs in size (Fig. 1A). The first exon
containing coding sequence was designated as exon 1, and analysis
of adjacent 5' flanking sequence revealed a high degree of
nucleotide sequence identity with the proximal promoter region
of the rat SLC3AJ homologue [221 including an experimentally
determined transcription start site and TATA box motif (Fig. 1B).
In human SLC3AI, introns interrupt the reading frame twice
(introns I and 6). The splice junction sequences are provided in
Table 2. All intron-exon boundaries conform closely to the
consensus pattern observed in eukaryotic genes [23]; all introns
begin with the canonical GT dinucleotide and terminate in an AG
dinucleotide. The genomic sequence of SLC3AJ was co-linear
with the human D2 eDNA sequence except a previously reported
difference in codon 446 (GGA vs. GGT), which does not affect the
amino acid sequence, and is a likely polymorphism.
Identification of SLC3AJ mutations
We used the genomic sequence information described above to
design oligonucleotide primers to facilitate PCR amplification of
individual exons from genomic DNA for single-strand conforma-
tional analysis (SSCA). Exons 2 to 9 could be amplified using
single pairs of intronic primers, but exons 1 and 10 each required
amplification of two overlapping regions to restrict the product
size to a range (150 to 250 bp) that provides for optimal SSCA
sensitivity [24].
Using SSCA, we identified five different mutations in SLC3AJ.
Figure 2 shows an autoradiograph obtained from non-denaturing
gels illustrating the abnormal migration of single-strand conform-
ers in our patients. A common abnormal single-strand conforma-
tion occurring in exon 8 was observed in nine patients. Direct
sequencing of this allele demonstrated it to be a previously
reported missense mutation, M467T [11]. Most of our patients
with this mutation are compound heterozygotes with a second as
yet undefined mutation.
We also observed three other distinct single-strand conformers
in exon 8 (Fig. 2, lower bands in lanes 6 and 12). Patient 22 (lane
12) exhibited compound heterozygosity for M467T and a second
distinct abnormal conformer, patient 16 (lane 6), exhibited an-
other unique SSCA pattern, and a third SSCA pattern was
observed in a single Swedish proband (data not shown). Sequenc-
ing of the conformer in patient 22 (lane 12) revealed a C to T
transition at nucleotide 1353 of the human D2 cDNA (Fig. 3, top).
This nucleotide change results in the substitution of tryptophan
for arginine-452 (designated as R452W), a residue conserved at
this position in human, rat, and rabbit sequences. This sequence
variant was not detected in any other cystinuric probands or in 97
normal control DNA samples examined by allele-specific oligo-
nucleotide hybridization. The non-conservative nature of R452W
and its absence in 194 normal chromosomes suggests that it is a
mutation rather than a polymorphism. The nucleotide change
responsible for R452W occurs in the context of a CpG dinucle-
otide (CGG), which is a known "hot spot" for mutations [25].
R452W
Y461H
Fig. 4. Proposed transmembrane topology of
SLC3AI (27) showing locations of five mutant
alleles identified in cystinuria probands.
Transmemhrane spanning regions are shown by
filled rectangles, and the position of introns in
the coding sequence are shown by short thick
lines intersecting the depicted protein
backbone. Mutations are indicated by open
c circles in their approximate location in the
protein.
The abnormal SSCA conformer derived from the Swedish
proband revealed a T to C transition at the nucleotide predicting
the replacement of tyrosine-461 with histidine (Fig. 3, bottom).
Tyrosine is a conserved resdue at this position in human, rat and
rabbit sequences. This abnormal conformer was not seen in 94
alleles from patients without the cystinuria phenotype screened by
SSCA. The non-conservative nature of the Y461H substitution
and its absence in 94 normal chromosomes is consistent with a
mutation.
Sequencing of the abnormal exon 8 conformer found in DNA
from patient 16 (lane 6) revealed a G to T transversion involving
the first nucleotide of intron 8, a mutation previously reported by
Horsford et al [15]. This nucleotide change alters the sequence of
the splice junction at this location such that the GT dinucleotide
normally present at the start of intron 8 is replaced by IT
(designated as 1500 + hG —÷ T). This sequence abnormality is
likely to cause aberrant splicing of pre-mRNA transcribed from
the gene as inferred from the documented effect of this type of
mutation in several other human genes [26].
A fourth distinct mutation was found in exon 4 (Fig. 2). DNA
from patient 20 (lane 3, exon 4) appeared homozygous for an
abnormal single-strand conformation. Sequencing of the allele
revealed a previously reported nonsense mutation at codon 270
(R270X) [14]. Figure 4 illustrates the approximate locations of the
mutations and splice junctions reported in this paper using a
proposed transmembrane topology model experimentally derived
for the SLC'3A1 gene product [271.
Discussion
Cystinuria is a common inherited disease with an estimated
incidence of between 1:7000 and 1:12000 worldwide [1]. Much
higher incidence rates are observed in certain ethnic populations.
The disorder carries substantial morbidity associated with recur-
rent nephrolithiasis such as pain, urinary tract obstruction, infec-
tion, and loss of renal function. Current pharmacological thera-
pies are directed at solubilizing cystine through disulfide exchange
with D-penicillamine or other compounds along with modulating
urinary volume and pH. Understanding the molecular basis for
this disorder may facilitate the development of additional thera-
pies aimed at replacing the defective gene product.
The first breakthrough in discerning the molecular genetics of
cystinuria occurred in 1994 with the identification of mutations in
the gene coding for a cystine transporter (SLC3A1) [11]. Since
then, additional mutations have been defined providing strong
evidence that SLC3A1 is indeed a cystinuria gene [12—14]. How-
ever, vast numbers of cystinuria probands exist for whom no
molecular genetic data exists. Furthermore, certain allelic subsets
of cystinuria as defined by cystine excretion in asymptomatic
heterozygous carriers may be caused by mutations at other loci.
Recent evidence indicates that type III cystinuria, characterized
by intermediate levels of urinary cystine in carriers, is not linked
to SLC3A], suggesting the existence of a second cystinuria locus
[13]. Clearly more studies are needed to fully document the
spectrum of SLC3AJ mutations and to delineate the basis for the
apparent genetic heterogeneity.
We have defined the complete intron-exon organization of the
SLC3AJ coding region to facilitate more rapid screening of
eystinuria probands for mutations. Knowledge of the genomic
organization of the gene has allowed us to develop a panel of
oligonucleotide primers for PCR amplification of each exon
directly from patient genomic DNA. This approach obviates the
need for the time consuming and labor intensive process of
establishing lymphoblastoid lines from patient lymphocytes to
examine the SLC3AI sequence through use of illegitimate tran-
scripts [11]. This should thus facilitate the systematic detection of
SLC3AJ genotypes in larger populations and may be more
amenable to the development of diagnostic screening assays.
We report here two novel SLC3..41 mutations associated with
cystinuria. Both are missense mutations in exon 8 (R452W and
Y461H) located in the intracellular loop between the second and
third transmembrane spanning segments according to the model
proposed by Mosckovitz et al (Fig. 4) [27]. The position of these
R270X
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mutations are close to that of two other alleles (M467T, M467K)
located within the third transmembrane segment. The M467T
mutation has been shown to reduce L-cystine transporter activity
of recombinant rBAT by —80% when expressed in Xenopus
oocytes [11]. The functional effects of M467T and the clustering of
mutations in this region of the protein suggest that there are
stringent structural requirements within this segment for normal
transporter function.
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